Sunday 31 October 2010

Insulin Actrapid




Insulin Actrapid may be available in the countries listed below.


Ingredient matches for Insulin Actrapid



Insulin Injection, Soluble

Insulin Injection, Soluble human (a derivative of Insulin Injection, Soluble) is reported as an ingredient of Insulin Actrapid in the following countries:


  • Bahrain

  • Czech Republic

  • Finland

  • Iceland

  • Israel

  • Romania

  • Russian Federation

  • Serbia

  • Sri Lanka

Insulin Injection, Soluble porcine or bovine (a derivative of Insulin Injection, Soluble) is reported as an ingredient of Insulin Actrapid in the following countries:


  • India

International Drug Name Search

Thursday 28 October 2010

Cefazolina Biocrom




Cefazolina Biocrom may be available in the countries listed below.


Ingredient matches for Cefazolina Biocrom



Cefazolin

Cefazolin is reported as an ingredient of Cefazolina Biocrom in the following countries:


  • Argentina

International Drug Name Search

Lomotil




In the US, Lomotil (atropine/diphenoxylate systemic) is a member of the drug class antidiarrheals and is used to treat Diarrhea.

US matches:

  • Lomotil

  • Lomotil Solution

  • Lomotil

UK matches:

  • Lomotil tablets (SPC)

Ingredient matches for Lomotil



Atropine

Atropine sulfate (a derivative of Atropine) is reported as an ingredient of Lomotil in the following countries:


  • Australia

  • Canada

  • Colombia

  • Ethiopia

  • Ghana

  • Hong Kong

  • India

  • Ireland

  • Nigeria

  • Oman

  • Singapore

  • South Africa

  • Thailand

  • Turkey

  • United Kingdom

  • United States

Diphenoxylate

Diphenoxylate hydrochloride (a derivative of Diphenoxylate) is reported as an ingredient of Lomotil in the following countries:


  • Australia

  • Canada

  • Colombia

  • Ethiopia

  • Ghana

  • Hong Kong

  • India

  • Ireland

  • Nigeria

  • Oman

  • Singapore

  • South Africa

  • Thailand

  • Turkey

  • United Kingdom

  • United States

  • Venezuela

Loperamide

Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Lomotil in the following countries:


  • Mexico

  • Philippines

International Drug Name Search

Glossary

SPC Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.

Tuesday 26 October 2010

Chuben




Chuben may be available in the countries listed below.


Ingredient matches for Chuben



Albendazole

Albendazole is reported as an ingredient of Chuben in the following countries:


  • Bangladesh

International Drug Name Search

Monday 25 October 2010

Follistim AQ


Follistim AQ is a brand name of follicle stimulating hormone, approved by the FDA in the following formulation(s):


FOLLISTIM AQ (follitropin alfa/beta - injectable; subcutaneous)



  • Manufacturer: ORGANON USA INC

    Approval date: March 23, 2004

    Strength(s): 300 IU/0.36ML [RLD], 600 IU/0.72ML [RLD]


  • Manufacturer: ORGANON USA INC

    Approval date: February 11, 2005

    Strength(s): 900 IU/1.08ML [RLD]


  • Manufacturer: ORGANON USA INC

    Approval date: August 26, 2005

    Strength(s): 150 IU/0.5ML [RLD], 75 IU/0.5ML [RLD]

Has a generic version of Follistim AQ been approved?


No. There is currently no therapeutically equivalent version of Follistim AQ available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Follistim AQ. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
    Patent 5,767,251
    Issued: June 16, 1998
    Inventor(s): Reddy; Vermuri B. & Hsiung; Nancy & Beck; Anton K. & Bernstine; Edward George
    Assignee(s): Genzyme Corporation
    Biologically active heterodimeric human fertility hormones composed of two different subunits, each subunit being synthesized in the same cell transformed by at least one cell expression vector having heterologous DNA encoding each subunit with each subunit being controlled by a separate promoter. Preferred human fertility hormones include hCG, hLH and hFSH.
    Patent expiration dates:

    • June 16, 2015
      ✓ 
      Drug substance




  • Liquid gonadotropin containing formulations
    Patent 5,929,028
    Issued: July 27, 1999
    Inventor(s): Skrabanja; Arnold Titus Philip & van den Oetelaar; Petrus Johannes Maria
    Assignee(s): Akzo Nobel, N.V.
    The invention concerns a liquid gonadotropin-containing formulation characterised in that the formulation comprises a gonadotropin and stabilising amounts of a polycarboxylic acid or a salt thereof and of a thioether compound. The particular proteins (e.g. LH, TSH, FSH, or HCG) are in admixture with the particular stabilizers in an aqueous solution. The preparations contain a sufficient amount of the polycarboxylic acid or a salt thereof, preferably sodium citrate, and a sufficient amount of the thioether compound, preferably methionine, to stabilize the protein. The preparations preferably also include a nonreducing disaccharide like sucrose, and a non-ionic surfactant.
    Patent expiration dates:

    • January 14, 2018
      ✓ 
      Patent use: METHOD OF TREATING INFERTILITY
      ✓ 
      Drug product




  • FSH formulation
    Patent 7,446,090
    Issued: November 4, 2008
    Inventor(s): Hoffmann; James Arthur & Lu; Jirong
    Assignee(s): Ares Trading S.A.
    This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.
    Patent expiration dates:

    • August 23, 2019
      ✓ 
      Drug product




  • FSH and FSH variant formulations, products and methods
    Patent 7,563,763
    Issued: July 21, 2009
    Inventor(s): Hoffmann; James Arthur & Lu; Jirong
    Assignee(s): Ares Trading S.A.
    This invention relates to FSH or a FSH variant containing an alpha and beta subunit contained in formulations, and articles of manufacture. The invention provides advantageous new proteins and nucleic acids, multi-use pharmaceutical solutions, formulations and products of said proteins and nucleic acids where none approved for commercial use had previously existed having such extended use indications. These products are particularly useful in therapeutic regimens for increasing serum levels of FSH or a FSH variant over a period of treatment. Thus, inter alia, the invention fills the need for convenient products of FSH or from a FSH variant.
    Patent expiration dates:

    • August 23, 2019
      ✓ 
      Patent use: METHOD OF TREATING INFERTILITY


    • August 23, 2019
      ✓ 
      Patent use: A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN



Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • June 28, 2013 - INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE

    • August 22, 2014 - NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE

See also...

  • Follistim AQ Consumer Information (Drugs.com)
  • Follistim AQ Consumer Information (Wolters Kluwer)
  • Follistim AQ Consumer Information (Cerner Multum)
  • Follistim AQ Advanced Consumer Information (Micromedex)
  • Follitropin Alfa Powder Consumer Information (Wolters Kluwer)
  • Follitropin Alfa Solution Consumer Information (Wolters Kluwer)
  • Follitropin Beta Consumer Information (Wolters Kluwer)
  • Follicle stimulating hormone Consumer Information (Cerner Multum)
  • Follitropin alfa Subcutaneous Advanced Consumer Information (Micromedex)
  • Follitropin beta Subcutaneous Advanced Consumer Information (Micromedex)

Sunday 24 October 2010

Saltos




Saltos may be available in the countries listed below.


Ingredient matches for Saltos



Salbutamol

Salbutamol is reported as an ingredient of Saltos in the following countries:


  • Russian Federation

International Drug Name Search

Saturday 23 October 2010

Nortan




Nortan may be available in the countries listed below.


Ingredient matches for Nortan



Atenolol

Atenolol is reported as an ingredient of Nortan in the following countries:


  • Turkey

International Drug Name Search

Friday 22 October 2010

Raxide




Raxide may be available in the countries listed below.


Ingredient matches for Raxide



Ranitidine

Ranitidine hydrochloride (a derivative of Ranitidine) is reported as an ingredient of Raxide in the following countries:


  • Philippines

International Drug Name Search

Spironolactone Altizide Biogaran




Spironolactone Altizide Biogaran may be available in the countries listed below.


Ingredient matches for Spironolactone Altizide Biogaran



Altizide

Altizide is reported as an ingredient of Spironolactone Altizide Biogaran in the following countries:


  • France

Spironolactone

Spironolactone is reported as an ingredient of Spironolactone Altizide Biogaran in the following countries:


  • France

International Drug Name Search

Tuesday 19 October 2010

Fluconazol-GRY




Fluconazol-GRY may be available in the countries listed below.


Ingredient matches for Fluconazol-GRY



Fluconazole

Fluconazole is reported as an ingredient of Fluconazol-GRY in the following countries:


  • Germany

International Drug Name Search

Thursday 14 October 2010

Opipramol-neuraxpharm




Opipramol-neuraxpharm may be available in the countries listed below.


Ingredient matches for Opipramol-neuraxpharm



Opipramol

Opipramol dihydrochloride (a derivative of Opipramol) is reported as an ingredient of Opipramol-neuraxpharm in the following countries:


  • Germany

International Drug Name Search

Saturday 9 October 2010

Inderalici




Inderalici may be available in the countries listed below.


Ingredient matches for Inderalici



Propranolol

Propranolol hydrochloride (a derivative of Propranolol) is reported as an ingredient of Inderalici in the following countries:


  • Mexico

International Drug Name Search

Friday 8 October 2010

Cefotim




Cefotim may be available in the countries listed below.


Ingredient matches for Cefotim



Cefotaxime

Cefotaxime is reported as an ingredient of Cefotim in the following countries:


  • Tunisia

International Drug Name Search

Monday 4 October 2010

brompheniramine/carbetapentane/phenylephrine


Generic Name: brompheniramine/carbetapentane/phenylephrine (brome fen IR a meen, kar be ta PEN tane, fen il EF rin)

Brand names: BetaTan, Pulmari, VazoTan, Seradex, V-Cof, Trexbrom


What is brompheniramine, carbetapentane and phenylephrine?

Carbetapentane is a cough suppressant.


Brompheniramine is an antihistamine. It blocks the effects of the naturally occurring chemical histamine in the body. Histamine can produce allergy symptoms such as sneezing, runny nose, and watery eyes.


Phenylephrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).


The combination of brompheniramine, carbetapentane and phenylephrine is used to treat cough and nasal congestion associated with allergies or the common cold.


Brompheniramine, carbetapentane and phenylephrine may also be used for purposes other than those listed in this medication guide.


What is the most important information I should know about brompheniramine, carbetapentane and phenylephrine?


Do not use brompheniramine, carbetapentane and phenylephrine if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious, life-threatening side effects can occur if you take brompheniramine, carbetapentane and phenylephrine before the MAO inhibitor has cleared from your body. This medication can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert. Avoid drinking alcohol. It can increase some of the side effects of brompheniramine, carbetapentane and phenylephrine. Do not use any other over-the-counter cough, cold, or allergy medications without first asking your doctor or pharmacist. Brompheniramine or phenylephrine are contained in many medicines available over the counter. If you take certain products together you may accidentally take too much of a certain drug. Read the label of any other medicine you are using to see if it contains brompheniramine, carbetapentane, or phenylephrine.

Avoid using other medicines that make you sleepy (such as cold medicine, pain medication, muscle relaxers, and medicine for seizures, depression or anxiety). They can add to sleepiness caused by brompheniramine, carbetapentane, and phenylephrine.


What should I discuss with my healthcare provider before taking brompheniramine, carbetapentane and phenylephrine?


Do not use brompheniramine, carbetapentane and phenylephrine if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious, life-threatening side effects can occur if you take brompheniramine, carbetapentane and phenylephrine before the MAO inhibitor has cleared from your body. Do not take this medication if you are allergic to brompheniramine, carbetapentane, or phenylephrine. These medications are contained in many cough, cold, and allergy medications.

Before taking this medication, tell your doctor if you are allergic to any drugs, or if you have:



  • a history of head injury or seizure disorder;




  • sleep apnea (periods of not breathing during sleep);




  • thyroid problems;




  • asthma, emphysema, or chronic obstructive pulmonary disease (COPD);




  • gallbladder disease;




  • Addison's disease;




  • diabetes;




  • glaucoma;




  • an ulcer or an obstruction in the stomach;




  • bladder problems or difficulty urinating;



  • an enlarged prostate;


  • high blood pressure, irregular heartbeats, or any type of heart disease;



  • kidney disease; or

  • liver disease.

If you have any of these conditions, you may not be able to use brompheniramine, carbetapentane, and phenylephrine, or you may need a dosage adjustment or special tests during treatment.


This medication may be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Brompheniramine, carbetapentane and phenylephrine can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby. Older adults may be more likely to have side effects from this medication.

How should I take brompheniramine, carbetapentane and phenylephrine?


Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.


Shake the oral suspension (liquid) well just before you measure a dose. To be sure you get the correct dose, measure the liquid with a marked measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.

Call your doctor if your symptoms do not improve, if they get worse, or if you develop a fever.


Store this medicine at room temperature away from moisture and heat.

See also: Brompheniramine/carbetapentane/phenylephrine dosage (in more detail)

What happens if I miss a dose?


Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at your next regularly scheduled time. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine.

Symptoms of a brompheniramine, carbetapentane and phenylephrine overdose may include dry mouth, large pupils, warmth or tingling under the skin, nausea, vomiting, restless feeling, or hallucinations.


What should I avoid while taking brompheniramine, carbetapentane and phenylephrine?


This medication can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert. Avoid drinking alcohol. It can increase some of the side effects of brompheniramine, carbetapentane and phenylephrine. Do not use any other over-the-counter cough, cold, or allergy medications without first asking your doctor or pharmacist. Brompheniramine or phenylephrine are contained in many medicines available over the counter. If you take certain products together you may accidentally take too much of a certain drug. Read the label of any other medicine you are using to see if it contains brompheniramine, carbetapentane, or phenylephrine.

Avoid using other medicines that make you sleepy (such as cold medicine, pain medication, muscle relaxers, and medicine for seizures, depression or anxiety). They can add to sleepiness caused by brompheniramine, carbetapentane, and phenylephrine.


Brompheniramine, carbetapentane and phenylephrine side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Less serious side effects are more likely to occur with this medication, such as:



  • dryness of the eyes, nose, or mouth;




  • drowsiness or dizziness;




  • blurred vision;




  • difficulty urinating; or




  • excitation (in children).



Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome. You may report side effects to FDA at 1-800-FDA-1088.


Brompheniramine/carbetapentane/phenylephrine Dosing Information


Usual Adult Dose for Allergic Rhinitis:

brompheniramine/carbetapentane/phenylephrine 4 mg-30 mg-7.5 mg/5 mL or brompheniramine/carbetapentane/phenylephrine 6 mg-25 mg-10 mg/5 mL oral suspension: 5 to 10 mL orally every 12 hours.
brompheniramine/carbetapentane/phenylephrine 6 mg-30 mg-10 mg/5 mL oral suspension: 5 mL orally every 6 hours. Not to exceed 4 doses in 24 hours.

Usual Adult Dose for Cold Symptoms:

brompheniramine/carbetapentane/phenylephrine 4 mg-30 mg-7.5 mg/5 mL or brompheniramine/carbetapentane/phenylephrine 6 mg-25 mg-10 mg/5 mL oral suspension: 5 to 10 mL orally every 12 hours.
brompheniramine/carbetapentane/phenylephrine 6 mg-30 mg-10 mg/5 mL oral suspension: 5 mL orally every 6 hours. Not to exceed 4 doses in 24 hours.

Usual Adult Dose for Cough and Nasal Congestion:

brompheniramine/carbetapentane/phenylephrine 4 mg-30 mg-7.5 mg/5 mL or brompheniramine/carbetapentane/phenylephrine 6 mg-25 mg-10 mg/5 mL oral suspension: 5 to 10 mL orally every 12 hours.
brompheniramine/carbetapentane/phenylephrine 6 mg-30 mg-10 mg/5 mL oral suspension: 5 mL orally every 6 hours. Not to exceed 4 doses in 24 hours.

Usual Pediatric Dose for Allergic Rhinitis:

brompheniramine/carbetapentane/phenylephrine 4 mg-30 mg-7.5 mg/5 mL oral suspension:
12 yrs or older: 5 to 10 mL orally every 12 hours.
6 yrs to 11 yrs: 2.5 to 5 mL orally every 12 hours.
2 yrs to 5 yrs: 1.25 to 2.5 mL orally every 12 hours.

brompheniramine/carbetapentane/phenylephrine 6 mg-25 mg-10 mg/5 mL oral suspension:
12 yrs or older: 5 to 10 mL orally every 12 hours.
6 yrs to 11 yrs: 5 mL orally every 12 hours.
2 yrs to 5 yrs: 2.5 mL orally every 12 hours.

brompheniramine/carbetapentane/phenylephrine 6 mg-30 mg-10 mg/5 mL oral suspension:
12 yrs or older: 5 mL orally every 6 hours. Not to exceed 4 doses in 24 hours.
6 yrs to 11 yrs: 2.5 mL orally every 6 hours. Not to exceed 4 doses in 24 hours.

Usual Pediatric Dose for Cold Symptoms:

brompheniramine/carbetapentane/phenylephrine 4 mg-30 mg-7.5 mg/5 mL oral suspension:
12 yrs or older: 5 to 10 mL orally every 12 hours.
6 yrs to 11 yrs: 2.5 to 5 mL orally every 12 hours.
2 yrs to 5 yrs: 1.25 to 2.5 mL orally every 12 hours.

brompheniramine/carbetapentane/phenylephrine 6 mg-25 mg-10 mg/5 mL oral suspension:
12 yrs or older: 5 to 10 mL orally every 12 hours.
6 yrs to 11 yrs: 5 mL orally every 12 hours.
2 yrs to 5 yrs: 2.5 mL orally every 12 hours.

brompheniramine/carbetapentane/phenylephrine 6 mg-30 mg-10 mg/5 mL oral suspension:
12 yrs or older: 5 mL orally every 6 hours. Not to exceed 4 doses in 24 hours.
6 yrs to 11 yrs: 2.5 mL orally every 6 hours. Not to exceed 4 doses in 24 hours.

Usual Pediatric Dose for Cough and Nasal Congestion:

brompheniramine/carbetapentane/phenylephrine 4 mg-30 mg-7.5 mg/5 mL oral suspension:
12 yrs or older: 5 to 10 mL orally every 12 hours.
6 yrs to 11 yrs: 2.5 to 5 mL orally every 12 hours.
2 yrs to 5 yrs: 1.25 to 2.5 mL orally every 12 hours.

brompheniramine/carbetapentane/phenylephrine 6 mg-25 mg-10 mg/5 mL oral suspension:
12 yrs or older: 5 to 10 mL orally every 12 hours.
6 yrs to 11 yrs: 5 mL orally every 12 hours.
2 yrs to 5 yrs: 2.5 mL orally every 12 hours.

brompheniramine/carbetapentane/phenylephrine 6 mg-30 mg-10 mg/5 mL oral suspension:
12 yrs or older: 5 mL orally every 6 hours. Not to exceed 4 doses in 24 hours.
6 yrs to 11 yrs: 2.5 mL orally every 6 hours. Not to exceed 4 doses in 24 hours.


What other drugs will affect brompheniramine, carbetapentane and phenylephrine?


There may be other drugs not listed that can affect brompheniramine, carbetapentane, and phenylephrine. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.



More brompheniramine/carbetapentane/phenylephrine resources


  • Brompheniramine/carbetapentane/phenylephrine Side Effects (in more detail)
  • Brompheniramine/carbetapentane/phenylephrine Dosage
  • Brompheniramine/carbetapentane/phenylephrine Use in Pregnancy & Breastfeeding
  • Brompheniramine/carbetapentane/phenylephrine Drug Interactions
  • Brompheniramine/carbetapentane/phenylephrine Support Group
  • 2 Reviews for Brompheniramine/carbetapentane/phenylephrine - Add your own review/rating


  • Brompheniramine/Carbetapentane/Phenylephrine Liquid MedFacts Consumer Leaflet (Wolters Kluwer)

  • BetaTan Suspension MedFacts Consumer Leaflet (Wolters Kluwer)

  • BetaTan Consumer Overview

  • Trexbrom Prescribing Information (FDA)



Compare brompheniramine/carbetapentane/phenylephrine with other medications


  • Cold Symptoms
  • Cough and Nasal Congestion
  • Hay Fever


Where can I get more information?


  • Your pharmacist has information about brompheniramine, carbetapentane and phenylephrine written for health professionals that you may read.

See also: brompheniramine/carbetapentane/phenylephrine side effects (in more detail)


Sunday 3 October 2010

Tilhasan




Tilhasan may be available in the countries listed below.


Ingredient matches for Tilhasan



Diltiazem

Diltiazem hydrochloride (a derivative of Diltiazem) is reported as an ingredient of Tilhasan in the following countries:


  • Vietnam

International Drug Name Search

Clozapine Mylan




Clozapine Mylan may be available in the countries listed below.


Ingredient matches for Clozapine Mylan



Clozapine

Clozapine is reported as an ingredient of Clozapine Mylan in the following countries:


  • France

International Drug Name Search

Saturday 2 October 2010

Kanrenol




Kanrenol may be available in the countries listed below.


Ingredient matches for Kanrenol



Potassium Canrenoate

Potassium Canrenoate is reported as an ingredient of Kanrenol in the following countries:


  • Italy

International Drug Name Search